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Abstract 
Targeted therapies have appeared as new treatment options for several disease types, including 
cancer and autoimmune disorders. Of several targets, tyrosine kinases (TKs) are among the most 
promising. Overexpression of TKs provides a target for novel therapeutic agents, including small 
molecule inhibitors of tyrosine kinases (TKI). Ibrutinib (PCI-32765) is a TKI of Bruton’s 
tyrosine kinase (Btk), a key kinase of the B-cell receptor signaling pathway that plays a 
significant role in the proliferation, differentiation and survival of B cells. In addition to 
inhibitory effects, recent studies have shown that ibrutinib has multiple immunomodulatory 
effects. It binds covalently to IL-2 inducible tyrosine kinase (Itk) in T lymphocytes and 
suppresses the survival of T-helper (Th) 2 cells. This changes the balance of Th1/Th2 cells 
toward Th1 subset, which are the main immune cells targeting tumor cells. The dual activity of 
ibrutinib has paid a great attention and several studies are evaluating the anti-tumor and 
immunomodulatory effects in cancer, autoimmune disorders and infectious diseases. In this 
article we review the inhibitory and immunomodulatory effects of ibrutinib in B-cell 
malignancies, autoimmune diseases and infections, as well as the communication between the 
Ror1 receptor tyrosine kinase and BCR and effects of ibrutinib on this crosstalk.  
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Introduction 
During the recent years, several targeted-therapy agents have been developed. These agents are 
more specific for tumor cells than normal cells [1]. Small molecule inhibitors (SMIs), including 
kinase inhibitors are potent agents for the treatment of cancer and autoimmune diseases [2-9]. 
These agents induce apoptosis of tumor cells through blocking molecules involved in cell 
survival [9].  
Among  several SMIs, ibrutinib (PCI-32765) has emerged as the first-in-class SMI targeting 
Bruton’s tyrosine kinase (Btk) and received FDA approval for the treatment of mantle cell 
lymphoma (MCL), chronic lymphocytic leukemia (CLL) [10] and recently was approved for the 
treatment of Waldenström’s Macroglobulinemia on January 29, 2015. 
Btk is involved in the B-cell receptor (BCR) signaling and is vital for many aspects of the B-cell 
development. Several studies have shown that ibrutinib binds to Btk with high affinity and leads 
to inhibition of BCR signaling, reducing the activation of malignant B cells and B cells involved 
in autoimmunity and infectious disease pathogenesis [11-14].  
BCR upregulation and its signaling pathway is a hallmark of the pathophysiology underlying 
MCL [15-16], CLL [17-21], diffuse large B-cell lymphoma (DLBCL) [22-23], and other B-cell 
malignancies by continuous stimulation of B cells through binding to a variety of antigens [24-
25]. Mutations in the Btk gene result in an immunodeficiency disorder named Bruton’s 
agammaglobulinemia or X-linked agammaglobulinemia (XLA), where patients have decreased, 
or lack of immunoglobulins and increased risk of infections [26].  
Ibrutinib treatment of leukemic CLL cells inhibits BCR signaling downstream of Btk with a 
decline in pro-survival cytokines and apoptosis of leukemic cells [27]. The safety and efficacy of 
ibrutinib in CLL and MCL might also suggest the use in other B-cell malignancies, autoimmune 
diseases and infections [10, 28-29]. Several trials are assessing ibrutinib in malignant B-cell 
disorders, including CLL, DLBCL, alone or in combination with other drugs (Table 1) [22].  
Several studies have demonstrated that ibrutinib targets other members of Tec family proteins. 
Ibrutinib has been shown to block IL-2 inducible tyrosine kinase (Itk) in T cells. T helper (Th) 1 
cells, also express another kinase called resting lymphocyte kinase (Rlk or Txk). Ibrutinib inhibits 
Itk in T cells but only Th1 cells will survive due to the activation of the Rlk survival pathway 
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[14]. Therefore, the balance between Th1/Th2 cells will skew toward Th1 type, which is 
important for tumor cell deletion, cells infected with intracellular pathogens and for the 
prevention of production of autoreactive antibodies production. The immunomodulatory activity 
and inhibition of Btk suggest that ibrutinib may be an interesting agent for targeted therapy.  
This article gives an overview of four major topics and recent findings, including 1) structure and 
function of Btk and Itk in BCR and T-cell receptor (TCR) signaling, 2) preclinical and clinical 
studies on the effects of ibrutinib in the treatment of malignant and autoimmune disorders, 3) 
communication between the Ror1 receptor tyrosine kinase and BCR and effects of ibrutinib on 
the crosstalk, and 4) novel roles of ibrutinib as a modulator of the immune system and the 
therapeutic applications in cancer, autoimmunity and infections. 
 
Btk structure and function 
Btk belongs to the Tec family of tyrosine kinases, which includes Btk, Itk, Bmx, Rlk, and Tec 
(Fig. 1). Tec family is the second largest family of non-receptor kinases after Src family. Btk 
structure consists of pleckstrin homology (PH), Tec homology, Src homology (SH)3, SH2 and 
SH1 domains [30]. The SH1 domain is the catalytic part of Btk (Figs. 1, 2).  
Btk is expressed in myeloid- and B-lymphoid cells but not in T cells and plasma cells [31-34]. 
Btk is important for several steps in the B-cell lineage development, including B-cell ontogeny, 
differentiation and survival [30, 35-36]. Btk binds to several cytosolic proteins to transduce 
signals to transcription factors (Fig. 2).  
B-cell development is strictly regulated by a balance between self-governing mechanisms (B-cell 
antigen receptor or pre-BCR/BCR), the bone marrow microenvironment and key cytokines, 
including interleukin (IL)-7. IL-7 is released by bone marrow stromal cells, leading to a properly 
assemble of pre-BCR. Pre-BCR is of importance for the further development of B cells and 
finally, the mature BCR is responsible for the mature B cell survival.  
The BCR is composed of the surface immunoglobulin, as the antigen binding site coupled with 
the signal transduction molecules, Igα/Igβ dimers (CD79A, CD79B) (Fig. 3). Stimulation of the 
BCR by antigen induces aggregation of BCR components, BCR oligomerization and BCR cluster 
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formation [37] that leads to phosphorylation of the immunoreceptor tyrosine-based activation 
motifs (ITAMs) of the cytoplasmic tails of Igα and Igβ. The latter is then activating Lyn and 
other Src family kinases (Fyn and Blk), which in turn activate Syk, Btk and phosphatidylinositol-
3 kinase (PI3K) isoforms.  
Following antigen binding to BCR, phosphatidylinositol-3, 4, 5- triphosphate (PIP3) levels are 
increased, leading to the recruitment of Btk to the cell membrane. Several proteins of the Src 
family, including Lyn and Syk, phosphorylate Btk at the tyrosine residue (Tyr) 551 at the 
activation loop of the kinase domain. Phosphorylation of Tyr 551 leads to autophosphorylation of 
Tyr 223 in the SH3 domain of Btk followed by activation of Btk kinase. The adapter proteins, 
including phospholipase Cγ2 (PLCγ2) and BLNK then translocate to the cell membrane and both 
will be phosphorylated by Btk [38]. Calcium will be mobilized and increased in the cytoplasm 
and protein kinase C (PKC) as well as nuclear factor-κB (NF-κB) activation occurs. Finally, NF-
κB activates several genes such as various cytokines, growth factors and receptor tyrosine kinases 
(RTKs) that control activation, proliferation, differentiation, and survival of B cells [30, 39]. Btk 
may play a crucial role in B-cell signaling and prevention of apoptosis of malignant B cells [40].  
Btk has critical roles in several hematopoietic cells signaling pathways. Due to the role of Btk in 
the BCR and cytokine receptors signaling, it is an attractive protein in targeted therapies of B-cell 
disorders, including malignant and autoimmune diseases. 
 
Overview of ibrutinib pharmacokinetics (PK) and pharmacodynamics (PD) 
SMIs of tyrosine kinases (TKIs) have been classified into five classes. Each type has different 
effects on the PK and PD of the drugs.  Type 1 TKIs are the most frequent type and are adenosine 
3-phosphate (ATP)-competitors. These inhibitors detect the active structure of the substrate and 
mimic ATP  [41].  
Type II targets the inactive conformation of kinases and occupies an extra hydrophobic pocket 
created by a conserved Asp–Phe–Gly (DFG) amino acid sequence. These inhibitors are more 
effective than type I and have better selectivity and slower off-rate [42-43]. Type III inhibitors 
bind to the allosteric site of the substrate near to the ATP binding pocket and are highly selective 
and specific for the target. Type IV TKIs forms an irreversible bond to the active site of the target 
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via binding to a cysteine (Cys) residue. Epidermal growth factor receptor (EGFR) inhibitor HKI-
272 and ibrutinib belong to this group [43]. Type V inhibitors are classified as a new type, and a 
few TKIs has been classified in this group. These inhibitors are bivalent compounds that target 
two distinct regions of the kinase. This bivalent binding will significantly increase affinities and 
enhanced selectivity of TKI for the targeted kinase. These new type of inhibitors might be the 
most useful drugs for personalized medicine and investigating signal transduction. 
 
Targeting BCR signaling has several therapeutic advantages. BCR signaling could be inhibited at 
different levels, for instance by antigen blocking, interrupting antigen binding or inhibition of 
BCR downstream components (Fig. 3).  
Currently, the lead compounds for targeting BCR signaling are kinase inhibitors that target the 
BCR or associated kinases as PI3K and spleen tyrosine kinase (Syk) (Fig. 3). Most investigations 
have focused on the development of ATP-competitive drugs that target the ATP-binding pocket 
of protein kinases. However, there are several challenges in the development of such inhibitors. 
Poor selectivity and competition with the ATP-binding pocket, due to high concentrations of 
endogenous ATP, have been observed and are considered as the major obstacles [3]. 
Irreversible kinase inhibitors (type IV) such as ibrutinib are attractive alternatives for ATP-
competitive drugs. These inhibitors show high selectivity, specificity and prolonged PD.  
Ibrutinib is the first covalent inhibitor of Btk reported by Pan et al. in 2007 and was developed to 
treat rheumatoid arthritis (RA) [44]. It has been developed from the reversible Btk inhibitor PCI-
29732. Ibrutinib is 16-fold more potent than the primary SMI PCI-29732 for inhibition of Btk. It 
binds covalently to Cys 481 in the ATP-binding pocket of Btk. The molecular formula is 
C25H24N6O2, with a molecular weight of 440.5 g/mol. Ibrutinib has an IC50 of 0.5 nM for Btk 
[44].  
PK studies have shown that ibrutinib is rapidly absorbed and eliminated after oral administration 
within 1–2 hours (h)  and binds to Btk for more than 24 h [10]. The drug is metabolized primarily 
by the liver. Several clinical trials have shown that the maximum tolerated dose for ibrutinib was 
not reached in both doses of 560 and 420 mg/day that are recommended for the treatment of 
MCL and CLL, respectively [13].  
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Ibrutinib binds to the non-phosphorylated Btk and stabilizes the inactive conformation by 
internalizing Tyr 551 and prevents the phosphorylation by other kinases such as Src. Ibrutinib 
inhibits other kinases, including Blk, Bmx, EGFR, Itk, and Janus kinase (JAK) 3 (IC50=0.5, 0.8, 
5.6, 10.7, and 16.1 nM, respectively) [45]. These kinases have a cysteine residue in the 
homologous location to Btk [30, 45]. Ibrutinib has shown to be 1000-fold more selective for 
inhibition of BCR signaling in B cells over TCR signaling in T cells.  
In spite of the several disadvantages of multi-targeted SMIs [3], the perspective of ibrutinib is 
mainly that of a special agent with dual effects. These positive effects will be discussed later. 
Moreover, Btk is expressed by other cells at lower levels than B cells [46-50] and therefore will 
not be highly affected by ibrutinib. 
 
Preclinical studies of ibrutinib in cancer 
Several preclinical studies have shown inhibition of BCR by ibrutinib [45], and direct 
cytotoxicity in DLBCL, MCL, hairy cell leukemia (HCL), and primary CLL cells [51-55]. 
Inhibition of cytokines and integrin associated signaling and leukemic cell migration have also 
been demonstrated by in vitro and in vivo models [56-57]. 
A rapid downregulation of BCR and NF-κB signaling pathways in vivo in CLL cells has also 
been noted during ibrutinib treatment [58]. Ibrutinib decreased the phosphorylation of PLCγ2 and 
Erk as well as reduced nuclear expression of NF-κB p50. Ibrutinib significantly inhibited the 
expression of CD69 and CD86 in tumor cells, independent of IgVH mutational status [59-60] or 
chromosome 17p deletion [61]. A stronger inhibition of BCR signaling in lymph node CLL cells 
was shown to be correlated with a higher rate of nodal response. Moreover, on-target effects of 
Btk inhibition by ibrutinib efficiently prevented pathways that stimulate tumor cell activation and 
proliferation in vivo [58]. 
Ibrutinib has inhibitory effects on malignant plasma cells. Combination treatment in multiple 
myeloma (MM) with ibrutinib, bortezomib and lenalidomide has shown significant increase in 
the observed cytotoxic effects. Ibrutinib prevented phosphorylation of the serine residues at 
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position 536 of the p65 subunit of NF-κB and blocked nuclear translocation and downregulated 
the anti-apoptotic proteins Bcl-xL, FLIP and survivin in myeloma cells [62].  
Effects of ibrutinib alone or in combination with bortezomib have been studied on Raji and 
Ramos Burkitt’s lymphoma cell lines [63]. Treatment with ibrutinib (0.5-6.0 µmol/L) and 
bortezomib (10-80 nmol/L) inhibited cell proliferation and survival in a dose- dependent and 
time-dependent manner with synergistic effects. Ibrutinib and bortezomib also inhibited the 
expression of intracellular NF-κB, Bcl-xL and c-IAP1 proteins and upregulated the expression of 
caspase-3.  
Ibrutinib efficacy has also been examined using breast cancer cell lines [64] and was shown to 
significantly reduce phosphorylation of the receptor tyrosine kinases EGFR, human epidermal 
growth factor receptor (HER) 2 and HER3 and suppressed the Akt and mitogen-activated protein 
kinases (MAPK) signaling pathway in HER2
+
 cells. Moreover, treatment of HER2
+
 cell lines 
with ibrutinib significantly decreased cell survival with IC50 values at nanomolar concentrations. 
Combination of the PI3K/mammalian target of rapamycin (mTOR) inhibitor BEZ235 with 
ibrutinib synergistically decreased cell viability of HER2
+
 breast cancer cells. The data suggested 
a therapeutic potential of ibrutinib in breast cancer and that the combination of PI3K inhibitors 
with ibrutinib might be considered as an effective approach in the treatment of breast cancer with 
activated ErbB receptors [64].  
Synergistic effects of ibrutinib and dual mTORC1/2 inhibitors have been examined in vitro using 
DLBCL cells [65]. The combination of ibrutinib and AZD2014, an mTOR inhibitor has strong 
synergistic effects in killing activated B-cell-like (ABC) subtype of DLBCL (ABC-DLBCL) cell 
lines. Simultaneous inhibition of Btk and mTOR induced apoptosis of DLBCL cell lines both in 
vitro and in vivo as well as tumor regression in a xenograft model. Inhibition of cap-dependent 
translation and the inhibition of NF-κB/IL-10/signal transducer and activator of transcription 
(STAT) 3 autocrine loop was shown to be the main mechanism of apoptosis and combined with 
disruption of the Btk and mTOR signaling pathways [65].  
The synergistic, additive and antagonistic drug combinations have been studied in ABC-DLBCL 
using a high-throughput screening method [66]. Combination of ibrutinib with a wide range of 
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compounds, including inhibitors of PI3K/Akt, mTOR, other BCR pathway, Bcl-2 family SMIs, 
and chemotherapies that are the standard treatments for DLBCL has shown favorable results [66]. 
Combination of ibrutinib and idelalisib (PI3Kδ inhibitor) has shown synergistic effects on 
inhibiting BCR signaling and targeting integrin-associated adhesion and migration of the tumor 
cells to the lymphoid organs. The combination results in malignant cells mobilization from the 
supporting niches into the blood and finally deprives the tumor cells of vital growth and survival 
signals [67].  
 
Clinical studies of ibrutinib in cancer 
Ibrutinib has been studied in several clinical settings for the treatment of lymphomas and 
leukemias (Tables 1, 2).  
Preliminary clinical trials in malignancies (refractory CLL, DLBCL, MCL, follicular lymphoma 
(FL), and marginal zone lymphoma (MZL)) indicated a proper safety profile at doses that 
achieved a higher than 95% enzyme occupancy and a high overall response rate (ORR) [55, 68-
70]. 
In a phase I trial, 56 patients with relapsed/refractory B-cell malignancies were treated with 
ibrutinib (Clinical trials.gov identifier: NCT00849654, Table 2). It was well-tolerated in doses up 
to 12.5 mg/ kg once/day [71]. The major side effects were rash, fatigue, diarrhea, nausea, and 
dyspepsia. The occupancy of Btk by ibrutinib was determined ex vivo by using the fluorescent 
probe PCI-33380. Complete Btk occupancy in the blood was observed at 2.5 mg/kg four times 
daily (q.i.d).  PK data indicated that ibrutinib was rapidly absorbed with a half-life of 6.3–10.8 h. 
Btk occupancy was continued for 24 h. Of 50 evaluated patients, ORR and progression free 
survival (PFS) were 60% and 13.6 months, respectively [71].  
In an open-label, phase Ib/II trial (NCT01105247 and NCT01217749, Table 2), ibrutinib was 
evaluated as initial therapy for elderly patients with CLL (n=29) or small lymphocytic leukemia 
(SLL) (n=2) [72]. Previously untreated patients older than 65 years with symptomatic CLL or 
SLL requiring therapy were enrolled. Patients received a 28 days cycle of 420 or 840 mg 
ibrutinib. However, in future studies only 420 mg was used as this dosage had the same effect as 
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840 mg. The primary endpoint was the safety of the dose-fixed regimen. Toxicity was mostly of 
grade 1-2, including diarrhea, nausea, fatigue and grade 3 infections, neutropenia, and 
thrombocytopenia. After a median follow-up of 22.1 months, 22 of 31 patients achieved an 
objective response (95%, CI=52.0-85.8), four patients showed a complete response (CR), one 
patient had a nodular partial response (PR), and 17 patients presented a PR [72]. 
Ibrutinib was evaluated in a phase II study of refractory MCL patients (n=111) (NCT01236391, 
Table 2) [29]. Eighty six percent of patients who had intermediate/high-risk disease were treated 
with ibrutinib at 560 mg q.i.d. The ORR, CR and PR rates were 65.8%, 17% and 49%, 
respectively. The most important side effects were mild atrial fibrillation, skin infections, nausea, 
diarrhea, pneumonia, abdominal pain, and fatigue [29]. 
During the median follow-up (15.3 months, range 1.9 to 22.3 months), 46 patients continued 
treatment, and 65 discontinued treatment. Discontinuation was due to disease progression, patient 
or investigator decision, and adverse effects (pneumonia, subdural hematomas, sepsis, cardiac 
arrest, elevated bilirubin level, respiratory failure, and metastatic adenocarcinoma). The results of 
this study led to the approval of ibrutinib by the FDA for the treatment of MCL with at least one 
prior therapy as a single agent [30]. Three months later, (February 12, 2014) ibrutinib was 
approved for the treatment of CLL, who have received at least one prior therapy [10]. 
Several trials are testing ibrutinib in combination with monoclonal antibodies (mAbs) and 
chemotherapy agents in B-cell malignances (Table 1, 2). 
In a phase Ib study (NCT01292135, Table 2), the safety and efficacy of ibrutinib were 
investigated in combination with chemo-immunotherapy in relapsed/refractory CLL patients 
[73]. Patients received bendamustine and/or rituximab (anti-CD20 antibody) (BR), 
cyclophosphamide, fludarabine, and rituximab (FCR) with ibrutinib (420 mg) until disease 
progression or toxicity were observed. Due to the lack of fludarabine-untreated patients, the 
recruitment of patients for FCR-ibrutinib arm was stopped. No toxicity in cycle one was observed 
in patients treated with BR-ibrutinib and FCR- ibrutinib (primary end point). The ORR was 
93.3% in BR-ibrutinib treated patients, and CR was 16.7% at the early stages of treatment that 
improved with the extension period (40%). 86.3% and 70.3% of patients showed no sign of 
disease progression after 12 and 36 months, respectively [73]. 
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In a phase Ib study (NCT01569750, Table 2) combination of ibrutinib with rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been evaluated for 
treatment-naive patients (n=33) with CD20-positive B-cell non-Hodgkin lymphoma (B-NHL) 
[74]. The primary endpoint was to identify a suitable dose of ibrutinib when combined with a 
standard R-CHOP regimen. The secondary endpoint was ORR and PK. Patients received 280, 
420, or 560 mg ibrutinib per day in combination with R-CHOP regimen every 21 days. The 
maximum tolerated dose was not achieved and 560 mg per day was the recommended dose for 
subsequent studies. The most important side effects (grade 3) were neutropenia (73%), 
thrombocytopenia (21%), febrile neutropenia, and anemia (18% each). The most often described 
adverse effects included febrile neutropenia (18%) and hypotension (6%). Thirty of 32 patients 
treated with one or more doses of combination regimen achieved an OR. All 18 patients with 
DLBCL who received the 560 mg dose showed an OR. Five of seven patients (71%)  with the 
germinal center B-cell-like subtype and two patients (100%) with the non-germinal center B-cell-
like subtype had a CR. R-CHOP did not change PK of ibrutinib, and ibrutinib did not affect the 
PK of vincristine [74].  
 
 
In a recent ongoing open-label, phase III trial (NCT01578707, Table 1), 391 patients with 
relapsed or refractory CLL or SLL were treated with daily ibrutinib or ofatumumab (anti-CD20 
antibody) [28]. PFS was the primary end point, and secondary end point was OS. Ibrutinib 
treatment showed significant improvement of PFS rate (88% at 6 months) compared to 
ofatumumab group with a median of 8.1 months, but the median duration was not reached in the 
ibrutinib treated patients. Ibrutinib also improved OS compared to ofatumumab group (90% vs. 
81% after 12 months). The ORR was 42.6% in the ibrutinib group compared to 4.1% in 
ofatumumab group (P<0.001) [28]. 
 
Safety and activity of ibrutinib plus rituximab have been evaluated in 40 patients with high-risk 
CLL [75]. In this phase II study patients with cytogenetic abnormalities (deletion 17p, TP53 
mutation or 11q deletion) or a short PFS (<36 months) after previous first-line 
chemoimmunotherapy were enrolled. Patients with symptomatic disease requiring therapy 
received 28-days cycles of once-daily ibrutinib (420 mg) combined with rituximab (375 mg/m(2) 
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, every week during cycle one and then once per cycle until cycle six) together with daily single-
agent ibrutinib (420 mg) until disease progression or unexpected toxicities. The primary endpoint 
was PFS in an intention-to-treat population [75].  
Grade 1-2 diarrhea (25%), bleeding events (33%), nausea or vomiting (38%), and fatigue (18%) 
were noted in patients. Five patients (13%) showed grade 3 infections (lung infections, upper 
respiratory tract infection, sepsis, and mucositis), no grade 4 or 5 infections were observed and 
one patient had a grade 4 neutropenia [75]. In this study with a follow-up of 16.8 months 
(median), 31 patients continued in the trial (14 of the 20 with del [17p] or TP53 mutation) and 
nine patients (22.5%) discontinued. Of discontinued patients, two died during the trial and six 
died after discontinuation of the study. One of the patients who died during the trial had an 
infectious complication that was unrelated to the study during the second cycle of study 
treatment, and one patient died during the remission due to an unknown reason. The other six 
patients died from infectious problems or after disease progression and two patients discontinued 
treatment due to the drug toxicity after the cycles five and two, respectively. Two patients 
discontinued the treatment due to resistant pneumonia and obstructive pulmonary complications 
[75].  
 
The combination of ibrutinib with bendamustine and rituximab is testing in a phase III study in 
relapsed CLL/SLL patients (the HELIOS trial) [76]. This trial is investigating if ibrutinib in 
combination with bendamustine and rituximab (BR) has significant benefits over BR alone. All 
patients receiving BR (six cycles) were randomized 1:1 to placebo or ibrutinib 420 mg/day. 
Treatment with ibrutinib and placebo was started in parallel with BR and continued until disease 
progression or unacceptable side effects were observed. The primary end point of this trial was 
PFS and the secondary end points were safety, ORR, OS, rate of minimal residual disease-
negative remissions, and patient-reported outcomes [76].  
 
Itk structure and signaling in T cells  
Itk (Emt, Tsk) belongs to the Tec family proteins and expresses in T lymphocytes, natural killer 
and mast cells [32, 77-83]. Itk has similar structural characteristics as Btk, including the common 
SH1, SH2, SH3, PH domains, Zinc binding motif (Btk homology, BH), and  a proline-rich region 
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(PRR) [84]. The PH domain is important to recruit the Itk kinase to the cell membrane and 
mediates the interaction of Itk with membrane bound phospholipids [85]. The SH3 domain is 
involved in the regulation of Itk and the interaction with PRR regions of other signaling proteins. 
The SH2 region is important for Itk localization and activation. It is critical for 
transphosphorylation and interaction of Itk with TCR-induced signaling proteins associate with 
the cell membrane. The SH2 domain also regulates the enzymatic activity of Itk. Disruption of 
this domain induces lack of kinase activity of Itk in contrast to the role of SH3 domain [86]. Itk is 
involved in TCR signaling as well as in Th1/Th2 balance and specifically regulates the function 
of Th2 lymphocytes. Lack of Itk has profound effects on Th2 cells [87].   
Stimulation of TCR promotes localization of Itk to the TCR/CD3/CD28 complex activating Src 
and Lck kinases followed by phosphorylation of CD3 [85]. Simultaneously, Zeta-chain-
associated protein kinase 70 (ZAP-70) binds to the activated CD3 and then Lck kinase 
phosphorylates ZAP-70 and activates the adaptor proteins, including the linker for activation of T 
cells (LAT) and SH2 domain containing leukocyte protein of 76 kDa (SLP-76) [88]. 
Subsequently, Itk is recruited to the cell membrane following activation of PI3K and 
accumulation of PIP3. In the cell membrane, Itk interacts with the pSLP-76/LAT complex via the 
Itk SH3 and SH2 domains following phosphorylation of Itk at Tyr 511 by Lck. Phosphorylated 
Itk activates the downstream signaling molecule PLCγ1 [84], which hydrolyses 
phosphatidylinositol-4,5-diphosphate (PIP2) to produce Inositol-3-phosphate (IP3) and 
diacylglycerol (DAG) [89], increasing calcium flux, Erk activation, actin reorganization (TCR-
induced actin polymerization), and cytokine release [90].  
Several Itk-SMIs are in preclinical development, but none has entered clinical trials. 
Considerable efforts have been made to develop Itk-SMIs to treat autoimmunity and allergy. The 
majority of Itk inhibitors lack selectivity and specificity to effectively suppress T-cell functions. 
However, a series of indazoles that show sub-nM inhibitory potency against Itk with strong 
cellular activity and kinase selectivity have recently been produced [91].  
 
Immunomodulatory role of ibrutinib 
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The broad activity of ibrutinib may have therapeutic indications through binding to the Itk kinase, 
which is of importance for Th2 cells. Ibrutinib has been shown to have immunomodulatory 
activity by inhibiting Itk in T cells derived from patients with CLL. Ibrutinib bond covalently to 
Itk at Cys 442 and occupy the active site followed by T cells inactivation [14]. However, in 
contrast to Th1 cells, Th2 cells were sensitive to ibrutinib and demonstrated reduced production 
of IL-4 in Th2 naive cells but no effects on IFN-γ production [14].  
Ibrutinib also inhibited Itk autophosphorylation at Tyr 180 in a dose-dependent manner and 
inactivated the downstream molecules IkBα, Junβ, STAT6, and nuclear factor of activated T-cells 
(NFAT) in primary CD4
+
 cells as well as in Jurkat cells. Junβ and STAT6 are critical in the IL-4 
signaling of Th2 cells. However, phosphorylation of upstream molecules such as Lck, ZAP70 
and LAT did not change. Moreover, a significant decrease in TCR-induced phospho-PLCγ1-Tyr 
783 dephosphorylation and inactivation in CD3/CD28-stimulated CD4
+
 T cells from CLL 
patients treated with ibrutinib was observed [11]. 
Resting lymphocyte kinase (Rlk) plays a redundant role for Itk in Th1 cells, but neither Th2 cells 
nor Jurkat cells expresses Rlk kinase. Jurkat cells transduced to express Rlk showed that the 
NFAT transcription factor, a downstream molecule of the TCR signaling pathway, was protected 
in the transfected cell line by the inhibitory effects of ibrutinib. Moreover, the intracellular 
calcium was significantly increased in the parent or Rlk untransfected Jurkat cells indicating that 
Rlk compensates for ibrutinib-inhibited Itk and provides an alternate activation platform for 
Itk/Rlk-expressing cells. CD4
+
 T cells from healthy controls and CLL patients showed a 
significant outgrowth of Th1 cells after ibrutinib treatment [14]. 
The immunomodulatory effects of ibrutinib are interesting, and further investigations are 
warranted. 
 
Preclinical studies of ibrutinib in autoimmune diseases and infections  
Any compound that inhibits BCR signaling may inactivate B cells in any diseases. The main goal 
of ibrutinib development was to block Btk and B-cell proliferation in RA and systemic lupus 
erythematous (lupus) (SLE) [45, 92]. Ibrutinib-related compounds inhibited the disease 
development in a murine RA model [44, 93]. Ibrutinib prevented collagen-induced arthritis 
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(CIA), as well as the production of autoantibodies and prevented the development of kidney 
disease in MRL-Fas (lpr) mice [45]. A Btk inhibitor (CGI1746) has been shown to prevent B cell 
proliferation and decrease the production of collagen-induced autoantibodies [94]. Btk inhibition 
diminished production of pro-inflammatory cytokines as tumor necrosis factor (TNF) α, IL-1 and 
IL-6, suggesting multiple targets of Btk inhibition in autoimmune diseases [94].  
The inhibitory effects of ibrutinib have been studied in several animal models, including reversed 
passive anaphylactic reaction, passive cutaneous anaphylaxis and collagen antibody-induced 
arthritis. High efficacy of ibrutinib in CIA models and animal models with immune-complex 
disorders was observed. Data suggest that ibrutinib may target other pro-inflammatory cells such 
as macrophages, mast cells and monocytes [92-93]. A link between Toll-like receptor (TLR) 9-
induced Btk activation has been described in PIR-B-deficient B-1 cells (paired immunoglobulin-
like receptor-B), inducing high titers of autoantibodies and autoimmunity [95]. In a mouse model 
with Btk overexpression in B cells, spontaneous formation of germinal centers, a significant 
increase of plasma cells, production of anti-nuclear autoantibodies (ANA), and induction of SLE-
like autoimmune disease was noted. These autoimmunity signs were significantly decreased in 
transgenic mice over-expressing a kinase-inactive Btk mutant. Treatment with ibrutinib reduced 
germinal center formation, decreased the number of plasma cells and inhibited the normal 
function of B cells [13]. Ibrutinib treatment also decreased humoral and cellular immunity and 
lupus nephritis in lupus-prone B6.Sle1 and B6.Sle1.Sle3 mice [12, 93].  
In a preclinical study, a dose-dependent occupancy of Btk (85–90%) was observed in the spleen 
of the lpr lupus mice 3 h after the final dose. The level of Btk inhibition was associated with the 
efficacy. Ibrutinib prevented the development of kidney disease measured as inhibition of 
production of autoantibodies such as anti-dsDNA antibodies, proteinuria and increase in blood 
urea. A significant decrease was noted in interstitial nephritis, perivascular inflammation and 
glomerulonephritis. Moreover, a complete healing of the  disease was also observed [30, 96].  
Ibrutinib has also been shown to prevent osteoclast-mediated bone loss [97]. Bone-resorbing 
osteoclasts play a crucial role in normal bone homeostasis and disorders as osteoporosis and RA. 
Tec family is essential for the differentiation of osteoclasts and inhibition of Btk might prevent 
the bone loss. Ibrutinib may inhibit osteoclastic bone resorption by suppressing osteoclast 
differentiation and function, downregulating the expression of NFATc1, the main transcription 
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factor for osteoclastogenesis and disrupts the formation of the actin ring in mature osteoclasts. 
Ibrutinib could also inhibit bone loss in a receptor activator of nuclear factor kappa-B ligand 
(RANKL)-induced osteoporosis mouse model [97].  
 A positive clinical effect of ibrutinib is not only mediated through inhibiting B cells, but also it is 
by changing the Th1/Th2 balance toward Th1 cells. Ibrutinib may be effective in inhibiting the 
growth of intracellular pathogens. Ibrutinib treatment has shown a significant increase of Th1 
cells as well as memory T cells in mice infected with intracellular pathogens [14]. 
In an interesting study, CLL cells were engrafted into mice and treated with ibrutinib or vehicle. 
Mice were then infected with Listeria monocytogenes expressing the immunodominant chicken 
ovalbumin (OVA) protein. Analysis of T cells showed a significant lower frequency of OVA-
specific CD8
+
 T-cell response in the leukemic vehicle treated control group as compared to 
ibrutinib treated mice. Ibrutinib not only restored the magnitude of the immune response, but also 
boosted the immune system against the infection. Non-leukemic mice and ibrutinib-treated 
leukemic mice cleared the infection by day 8, but in leukemic mice treated with vehicle Listeria 
contamination were noted within the liver. Rechallenge of ibrutinib treated mice with Listeria 
indicated no loss of a functional immunologic memory as determined by the measurement of 
CD62L
+
/CD4
+
 and CD62L
+
/CD8
+
 cells [14]. 
 
The human immunodeficiency virus-1 (HIV-1) Nef virulence protein interacts with host cell-
signaling molecules. Nef binds to the SH3 domain of Src family kinases (Hck, Lyn, and c-Src), 
which are activating kinases of importance for viral activity, including infectivity, replication and 
HLA down-regulation [98]. Itk, Bmx and Btk but not Tec or Txk are present in HIV target cells, 
and they are linked to HIV-1 infectivity [99]. Nef interacts with intracytoplasmic kinases of the 
Tec enzyme family and maybe a link between HIV-1 and Itk during the viral life cycle. A 
specific/selective SMI of Itk (BMS-509744) suppressed the wild-type HIV-1 activity, but not the 
Nef-defective mutant. Nef induced activation of Itk in transfected cells that were sensitive to SMI 
treatment. Ibrutinib might have the same effects as BMS-509744 and not only block the HIV 
interaction with cells, but also inhibit the viral infectivity and spread through activation of Th1 
cells [99]. 
17 
 
Itk also regulates T cell signaling by organizing actin polymerization, polarization, recruitment of 
kinases and adapter proteins as well as controlling different steps of HIV-1 infectivity, including 
virion assembly and release [100]. Itk and group-specific antigen (Gag) protein colocalized at the 
membrane and are concentrated at sites of F-actin accumulation and lipid rafts in infected T cells. 
Itk specific SMIs inhibit F-actin capping, disturb Gag-Itk colocalization, block virus particle 
release, and reduce HIV duplication in human CD4
+
 T cells. Targeting Itk by SMIs such as 
ibrutinib and other selective Itk inhibitors might prevent HIV-1 egress and control HIV infection 
[100]. 
Itk kinase activation is also shown to play a central role in the replication of influenza virus in T 
cells [101]. Treatment of influenza-infected patients with ibrutinib might have therapeutic effects 
by blocking Itk [102].  
Inhibition of Itk by ibrutinib may constitute a novel non-steroidal treatment for allergy and other 
T-cell mediated hypersensitivities [103-106]. Itk is necessary for FcεRI aggregation and signaling 
in basophils. Stimulation of basophils with IgE, followed by treatment with ibrutinib reduced the 
expression of CD63, histamine, leukotriene C4 (LTC4) and IL-4 secretion at an IC50 of 3-6 nM. 
Expression of CD203c, CD11b and the cytosolic calcium response was inhibited at an IC50 of 30-
40 nM. The results might indicate that Btk is involved in IgE-mediated activation of human 
basophils [107]. 
Ibrutinib may inhibit B-cell activation and proliferation and to inhibit activation through IgG and 
FcεRI but not TLR4 [108]. Several studies have shown a role for Btk in macrophage activation 
through TLR4 [109]. The ability to block TLR signaling may be of benefit in RA as TLR 
signaling might contribute to the development of RA mediated by endogenous TLR ligands [109-
110]. 
 
Effects of ibrutinib on the crosstalk between the BCR and Ror1 receptor tyrosine 
kinase 
Ror1 receptor tyrosine kinase is expressed in several solid tumors and hematologic malignancies 
and has important roles in tumor cells survival, migration and metastasis [111-114]. Cross-
communication between BCR and Ror1 signaling pathway has been recently described [115]. It 
has been shown that BCR and Ror1 modulate each other in a counterbalancing manner that is 
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important for tumor cell survival in acute lymphocytic leukemia (ALL) [115]. Downregulation of 
BCR by dasatinib and inactivation of Akt, as well as inhibition of Igα and Igβ, induced 
upregulation of Ror1 in ALL cells. Downregulation of both Ror1 and BCR induced 
dephosphorylation of Akt, inhibited cell growth and increased tumor cell killing. However, 
downregulation of either Ror1 or BCR alone did not induce the same effects, suggesting 
complimentary effects. The data also indicated an intracellular link (PI3K/Akt) between the pre-
BCR and Ror1 signaling pathways, in which Btk was of importance [115].  
Based on the current findings, an interesting model has been suggested. According to this model, 
during the development of B cells in bone marrow, B cells at the pre-BII stage upregulate Ror1 
and the pre-BCR complex. Pre-BCR activates the Akt signaling pathway to induce B-cell 
proliferation and inhibit differentiation. To maintain B-cell development, the complex of pre-
BCR is internalized and surrogate light chain is replaced by κ or λ chains. Surface expression of 
the mature BCR complex promotes B-cell differentiation. Signaling by the mature BCR activates 
the BLNK/PLCγ2 and this complex inhibits Akt activation and promotes cell maturation. At this 
stage, loss of active Akt is deleterious for cells, but transient expression of Ror1 provides an 
alternative mechanism for cell survival through activation of the Mek/Erk signaling pathway. 
Ror1 expression drives partial reactivation of Akt and provides additional signals for cell 
survival. In t(1;19) pre-B ALL cells, the E2A-PBX1 fusion protein contributed to B-cell arrest at 
the pre-BII stage and both the pre-BCR complex and Ror1 expression provided sustained survival 
signals for the malignant B-cell progenitors [115-116]. These data might suggest that the 
common pathways, which are used by BCR and Ror1 are downstream of Btk and might be 
affected by ibrutinib. 
Part of the effects of ibrutinib on Btk and inactivation of BCR signaling might indirectly be due 
to downregulation of Ror1. However, downregulation of BCR may induce upregulation of Ror1 
expression and activation in ibrutinib treated cells. This phenomenon may compromise the effects 
of ibrutinib and induce ibrutinib resistance. Combination of Ror1 inhibitors [3, 114] and ibrutinib 
might have a synergic anti-tumor effects. Further investigations are warranted to evaluate these 
effects. 
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Ibrutinib side-effects and tumor cells resistance 
Ibrutinib is well tolerated. Side effects are mainly grade 1-2, including dyspnea, rash, nausea, 
diarrhea, fatigue, upper respiratory tract infections, and edema. These side effects seldom require 
therapeutic intervention [72, 117]. Treatment delays or discontinuation due to side effects of 
ibrutinib are rare. Major toxicities, including grade 3 and 4 have been observed in CLL and MCL 
and were mostly infections, as pneumonias, but the relation is uncertain [72, 117]. Ibrutinib does 
not seem to induce myelosuppression [93, 118]. Ibrutinib has been shown to affect platelet 
functions and based on preclinical observations it is suggested that Btk might play a role in 
platelet aggregation [119] by transferring signals from the platelet glycoprotein Ib (GPIb). Btk is 
also important for signaling via the collagen receptor GPVI in platelets [120]. An increased risk 
of bleeding has been observed in some patients [121]. Notably, patients with XLA, who have 
defective Btk, do not seem to have an increased risk for bleeding events [122].  
 
Resistance to SMIs through mutations (off-target) during treatment may occur. Mutations that 
change drug binding to the target have been observed in several cancers, including EGFR [123-
124] and anaplastic lymphoma kinase (Alk) [125] in lung cancer, fms-like tyrosine kinase 3 
(FLT3) in acute myeloid leukemia (AML) [126] and Kit in gastrointestinal stromal tumors [127]. 
Approximately 30% of CLL and MCL patients exhibit resistance against ibrutinib [29, 128]. 
Recurrent mutations of Btk and its substrate PLCγ2 will induce resistance in a subset of CLL and 
MCL patients who have been well responded to the treatment or get prolonged treatment with 
ibrutinib relapse. A cysteine-to-serine (Btk
C481S
) mutation in Btk at the binding site of ibrutinib 
has been reported [129-130]. The mutation changed the covalent binding between the ibrutinib 
and Btk (decreased binding affinity) creating a protein that is reversibly inhibited by ibrutinib. 
Moreover, three mutations in PLCγ2 (S707Y, R665W, and L845F) (downstream of Btk) induced 
tumor cell resistance to ibrutinib. These mutations are gain-of-function mutations leading to 
constant activation of BCR that is independent of Btk [130]. 
 
Concluding remarks  
Immunomodulatory drugs are emerging as new and valuable generation of SMIs. These 
molecules target special kinases and have multiple therapeutic effects in various disorders. This 
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generation of first-in-class drugs may have several benefits for the targeted therapy of cancer, 
autoimmune and infectious diseases. Ibrutinib is an example of this new generation. The drug 
targets B cells by binding to Btk, which is upregulated in most B-cell malignancies. However, 
due to the multi-targeted characteristics, it also binds to Itk in Th cells and inhibits proliferation 
and differentiation of Th2 cells. Th1 cells are rescued from the inhibitory effects of ibrutinib 
through the activation of Rlk compensatory signaling, which is not expresses in Th2 cells. 
Ibrutinib may also emerge as an immune modulating agent. There is to our knowledge not yet 
any clinical trial testing the effects of ibrutinib in autoimmune and allergic disorders or infectious 
diseases. Ibrutinib might, however, be an effective inhibitor of autoreactive B cells and inhibits 
Th2 cells to prevent progression of B-cell related disorders. Further investigations are warranted 
to study the effects on the immune system and reveal other unknown therapeutic effects of 
ibrutinib.  
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Figures legend: 
Figure 1. Tec family structure. Members of Tec family kinases are schematically depicted showing the 
structural domains. 
 
Figure 2. BTK structure and associated intracellular proteins. BTK is the central key tyrosine kinase 
in BCR signaling pathway. Several intracellular molecules bind to different domains of BTK and 
transduce signals. 
 
Figure 3. Schematic presentation of the BCR signaling pathway and the targets for different small 
molecule inhibitors (SMI). The inhibitors prevent phosphorylation and activation of several enzymes 
involved in survival, proliferation and differentiation of B cells. 
 
 
 
 
